A Study of the Correlation Between the Debilitating State of the Elderly and Propofol Sensitivity

In an aging society, there is a surge in the number of surgeries for elderly patients in hospitals, and the elderly are at greater risk of anesthesia due to their own characteristics: slowing metabolism, decreasing resistance, and decreasing physical function, and increased sensitivity to propofol. However, there are large individual differences, and anesthesiologists have found that they cannot judge a patient's sensitivity to anesthetic drugs based on age alone. Patients with different levels of debilitation have different sensitivities to propofol. The use of measuring telomere length to assess the debilitating state of the elderly is a novel and reliable assessment method. Then the sensitivity to propofol of people with different debilitating states was studied, so as to guide anesthesiologists to use drugs safely and reasonably, with a view to realizing the purpose of precise anesthesia.

Study Overview

• Status: Completed
• Conditions: Frailty; Telomere
• Intervention / Treatment: Drug: propofol

Detailed Description

Part I: A study of the correlation between telomere length and somatic debilitation status in older adults Telomere length was measured by fluorescent quantitative PCR, and subjects were assessed for somatic frailty using the Edmonton Scale (EFS).

1. Perform a correlation analysis between telomere length and Edmonton debility score.
2. Comparison of telomere length differences between Edmonton debility subgroups.
3. Subjects were categorized into "not debilitated" and "debilitated" dichotomous variables according to Edmonton debilitation ratings. The strength of the predictive power of telomere length for frailty was determined using the area under the ROC curve (AUC) using the operator operating characteristic curve ROC treatment .

Part II: Correlation between telomere length and propofol sensitivity in elderly surgical patients A total of 128 patients undergoing lower limb surgery under subarachnoid block in the Second Hospital of Shanxi Medical University were selected and divided into non-frailty group and frailty group.Propofol was pumped at a rate of 20 mg/kg/h with a micropump at 15 minutes after subarachnoid block, and the pumping rate was reduced to 10 mg/kg/h after 1 minute.Stop the infusion when consciousness is absent and observe the time of loss of consciousness (time of loss of eyelash reflex).

intraoperative recording of the time of loss of consciousness (time of disappearance of eyelash reflex), time of awakening, and dosage of propofol in both groups; recording of the time of admission to the room (T0), the time after completion of subarachnoid blockade (T1), the time after 1min of pumping propofol (T2), the time after 5min of pumping propofol (T3), the time after 10min of pumping propofol (T4), the time after 15min of pumping propofol ( T5), after pumping propofol for 20 min (T6), after pumping propofol for 25 min (T7), and after pumping propofol for 30 min (T8); mean arterial pressure (MAP), heart rate (HR), and electroencephalographic dual-frequency index (BIS value) at nine time points; the incidence of adverse reactions (hypotension, bradycardia, and respiratory depression) was recorded for the two groups.

Research hypotheses:

1. There is a difference in propofol sensitivity indices between the debilitated and non-debilitated groups. [time to loss of consciousness; heart rate; MAP; BIS; occurrence of adverse effects; use of vasoactive drugs].
2. There was a difference in telomere length between the debilitated and non-debilitated groups.
3. Among all patients, those with shorter telomere lengths were more sensitive to propofol, and the patients' sensitivity to propofol could be predicted by their telomere lengths.

experimental procedure

1. Comparison of demographic information between the two groups
2. Comparison of propofol sensitivity between the two groups
3. Comparison of telomere length between the two groups.
4. To analyze the correlation between telomere length and its demographic and clinical characteristics for the two groups, the multiple linear regression model was further used to analyze the factors associated with telomere length for all patients, taking the independent variables of gender, age, BMI and other demographic information, and the dependent variable of telomere length. Again, it is shown that there is no significant linear relationship between patients' demographic information and telomere length. Then explain how factors that have a linear correlation will affect the patient's sensitivity to propofol.
5. Analyze the correlation between telomere length and propofol sensitivity indexes, and then use linear regression model to further regress telomere length on the indexes with correlation. The independent variable was selected as telomere length and the dependent variable was time to loss of consciousness/heart rate/MAP/BIS. the model was subjected to analysis of variance (ANOVA) to obtain the β and P values, which indicated whether the model was statistically significant and whether the telomere length could predict several of the above indexes.

• Study Type: Interventional
• Enrollment (Actual): 128
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• China
  • Shanxi
    • Taiyuan, Shanxi, China, 030001
      • Second Hospital of Shanxi Medical University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age ≥ 65 years
• American Society of Anesthesiologists (ASA) Classification I-IV
• No previous history of central nervous system disease, no history of psychiatric disorders, no contraindications to anesthesia
• No use of sedative drugs or opioids within 24h
• Approval and consent by the Ethics Committee of Shanxi Medical University and written informed consent by the patient (or authorized delegate)

Exclusion Criteria:

• leukemia patient
• Patients with hearing and visual impairments, communication disorders, inability to complete the debilitating state test
• Patient or family refused to participate in this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: frail group; Edmonton scores three or more points	Drug: propofol; Fifteen minutes after the subarachnoid block, propofol was pumped in at a rate of 20 mg/kg/h with a micro pump, and the pumping rate was reduced to 10 mg/kg/h after 1 min. The infusion was stopped when the consciousness disappeared, and the time of the disappearance of consciousness was observed (time of the disappearance of eyelash reflex).; Other Names: Ropivacaine
Experimental: non-frail group; Edmonton scores zero to three	Drug: propofol; Fifteen minutes after the subarachnoid block, propofol was pumped in at a rate of 20 mg/kg/h with a micro pump, and the pumping rate was reduced to 10 mg/kg/h after 1 min. The infusion was stopped when the consciousness disappeared, and the time of the disappearance of consciousness was observed (time of the disappearance of eyelash reflex).; Other Names: Ropivacaine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
telomere length	Differences in telomere length	24 hours
Loss of consciousness time	Differences in loss of consciousness time	24 hours
awakening time	Differences in awakening time	24 hours
Propofol dosage	Differences in Propofol dosage	24 hours
Mean Arterial Pressure (MAP)	Differences in Mean Arterial Pressure (MAP)	24 hours
heart rate	Differences in heart rate	24 hours
Electroencephalographic dual frequency index (BIS value)	Differences in Electroencephalographic dual frequency index (BIS value)	24 hours
Incidence of adverse effects (hypotension, bradycardia, respiratory depression)	Incidence of adverse effects (hypotension, bradycardia, respiratory depression)	24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Use of vasoactive drugs	Use of vasoactive drugs	24 hours

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Checklist form: Sex, age, ASA classification, smoking history, drinking history, comorbidities		24 hours
BMI	weight and height will be combined to report BMI in kg/m^2	24 hours

Collaborators and Investigators

• Sponsor: Second Hospital of Shanxi Medical University

Study record dates

Study Major Dates

• Study Start (Actual): January 20, 2024
• Primary Completion (Actual): June 20, 2024
• Study Completion (Actual): October 20, 2024

Study Registration Dates

• First Submitted: November 19, 2024
• First Submitted That Met QC Criteria: March 10, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 10, 2025
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Keywords: propofol; Frailty; telomere length
• Additional Relevant MeSH Terms: Pathologic Processes; Frailty; Physiological Effects of Drugs; Peripheral Nervous System Agents; Anesthetics, Local; Anesthetics; Central Nervous System Depressants; Sensory System Agents; Hypnotics and Sedatives; Anesthetics, Intravenous; Anesthetics, General; Ropivacaine; Propofol
• Other Study ID Numbers: yuewei20240110

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No